ABBV-744 clinical trial phase 2 data Things To Know Before You Buy
These side effects ended up notably milder when compared to an inhibitor of the two bromodomains. An in depth molecular Assessment also uncovered that ABBV-744 preferentially inhibits the expression of Androgen Receptor (AR)-dependent genes. ― Stephen Taylor88 These preclinical studies provide paradigms for potential clinical trials in AML, and